Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 24;5(4):896-899.
doi: 10.1002/jha2.966. eCollection 2024 Aug.

Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma

Abdullah N M Alqahtani  1 , Sandrine Jayne  1 , Matthew J Ahearne  1   2 , Christopher S Trethewey  1   3 , Sai S Duraisingham  4 , Susann Lehmann  5 , Caroline M Cowley  6 , Martin J S Dyer  1   2 , Harriet S Walter  1   7
Affiliations

Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma

Abdullah N M Alqahtani et al. EJHaem. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Martin J. S. Dyer has received research funding from Gilead Sciences. Harriet S. Walter has received research funding from Gilead Sciences. Sandrine Jayne has received research funding from Gilead Sciences. All the other authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
(A) Treatment timelines for the three exceptional responder patients. Red diamonds correspond to the time of clinical progression, (B–D) Droplet frequency plots corresponding to serial ddPCR analysis during treatment with tirabrutinib (timeline) performed for patient 201‐139 detected with t(11;14) translocation breakpoint assay (B), for patient 201‐162 with t(11;14) translocation breakpoint (top panel) and KMT2D (c.8315_8316insT) (bottom panel) assays (C), for patient 201‐170 with t(11;14) translocation breakpoint (top panel), TP53 (c.581T > G) (middle panel) and ATM (c.8399A > C) (bottom panel) assays (D) with additional biopsy positive and human genomic DNA (hgDNA) negative controls. The pink line indicates amplitude thresholds. Mutant droplets are indicated in blue; negative droplets in grey. ctDNA, circulating tumor DNA; CTC, circulating tumor cells; NTC, no template control. ddPCR assays were run at different time points and figures were constructed for clarity.
See this image and copyright information in PMC

References

    1. Burger JA. Bruton tyrosine kinase inhibitors: present and future. Cancer J. 2019;25(6):386–393. 10.1097/PPO.0000000000000412 - DOI - PMC - PubMed
    1. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926. - PMC - PubMed
    1. Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, et al. Effect of ibrutinib with R‐CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643–1653.e3. - PMC - PubMed
    1. Cooper A, Tumuluru S, Kissick K, Venkataraman G, Song JY, Lytle A, et al. CD5 gene signature identifies diffuse large B‐cell lymphomas sensitive to Bruton's tyrosine kinase inhibition. J Clin Oncol. 2023:JCO2301574. 10.1200/JCO.23.01574 - DOI - PubMed
    1. Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, et al. Phase I/II study of tirabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23(1):122–133. - PMC - PubMed

LinkOut - more resources